CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Post-LOE

betamethasone dipropionate; calcipotriene

Ichnos Glenmark Innovation

ANDATOPICALAEROSOL, FOAM

Approved

Mar 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE (betamethasone dipropionate; calcipotriene) by Ichnos Glenmark Innovation is 3 analog and betamethasone dipropionate as a synthetic corticosteroid. Approved for psoriasis. First approved in 2023.

Drug data last refreshed Yesterday

Mechanism of Action

3 analog and betamethasone dipropionate as a synthetic corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in the treatment of plaque psoriasis of the scalp and body are unknown.

Indications (1)

psoriasis

Company

Worked on CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.